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The intracellular degradation of newly synthesized 
collagen is a cellular pathway that accounts for the 
destruction of 10-60% of collagen synthesized by a vari­
ety of cell types prior to secretion. This pathway can 
serve in a regulatory role to limit the secretion of defec­
tive molecules, and, in response to some extracellular 
mediators, regulates the amount and type of collagens 
secreted. In addition, this pathway may contribute to the 
pathogenesis of a variety of conditions affecting the 
extracellular matrix including fibrosis, diabetes mellitus, 
and scurvy. 
Collagen is the most abundant extracellular structural protein 
of higher organisms. Although the process by which cells pro­
duce collagen has been described in considerable detail, the 
mechanisms which regulate the production of this macromole­
cule are not fully understood. Recent evidence indicates that in 
addition to tra�scriptional and translational controls, collagen 
producing cells can modulate collagen production by degrading 
a portion of newly synthesized collagen prior to secretion. In 
this context, this review will describe: (1) the pathway of 
intracellular degradation of collagen including the experimental 
evidence that demonstrates this pathway in various cells and 
tissues; (2) the role of intracellular degradation as an important 
mechanism by which cells regulate both the quality and the 
quantity of collagen produced; and (3) the relationship between 
the intracellular degradation of newly synthesized collagen and 
some disease states. 
THE PATHWAY OF INTRACELLULAR 
DEGRADATION OF COLLAGEN: TECHNICAL 
CONSIDERATIONS 
Certain aspects of collagen biosynthesis provide important 
means for quantifying the intracellular degradation of newly 
synthesized collagen (see reference 1 for review). Specifically, 
the modification of prolyl and lysyl residues in the nascent 
polypeptide of the newly synthesized pro collagen chain serve 
as specific markers for collagen (Figure). In this regard, the 
hydroxylation of proline and lysine are considered to be rela­
tively specific for collagen in most tissues. Thus, although it is 
known that hydroxylation of prolyl residues does occur in 
elastin [2] and in the collagenous regions of the C1q component 
of complement [3] and acetylcholinesterase [4], quantitatively, 
the vast amount of hydroxyproline is found in collagen. Indeed, 
the hydroxyproline content of tissues is generally utilized as a 
measure of collagen content, and the error due to hydroxypro­
line from other sources has been estimated to be less than 5% 
[5]. Importantly, since hydroxyproline and hydroxylysine are 
fonned only after the synthesis of the polypeptide chain of the 
collagen molecule [1], the presence of small peptide fragments 
containing these modified amino acids can be utilized as a 
marker of collagen degradation. The analysis of such low mo­
lecular weight hydroxylated derivatives forms the basis for 
studies regarding intracellular degradation of collagen. 
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Historical Aspects 
A large number of early studies demonstrated that, following 
the addition of labeled proline to cells or tissues in vitro or to 
animals in vivo, there was rapid formation of low molecular 
weight peptides containing hydroxyproline (Table). Although 
at the time the significance of these low molecular weight 
hydroxyproline containing molecules was unclear, it is now 
recognized that they represented rapid degradation of newly 
synthesized collagenous chains. Moreover, although the major­
ity of these studies were not designed to address the question 
of the site of the rapid degradation of newly synthesized colla­
gen, as will be described below, considerable experimental 
evidence exists in these reports in support of an intracellular 
site for this process. 
Experimental Proof of an Intracellular Site for the 
Degradation of Newly Synthesized Collagen 
The evidence indicating that rapid degradation of newly 
synthesized collagen occurs at an intracellular location is now 
clearly established. Although early investigators considered the 
possibility that the rapid formation of low molecular weight 
hydroxyproline containing species indicated intracellular deg­
radation of newly synthesized collagen [6-12], it was the studies 
of Bienkowski and colleagues that definitively demonstrated 
the intracellular location for the degradation of newly synthe­
sized collagen [13,14]. Utilizing cultured lung fibroblasts [1:3], 
these studies demonstrated that, following the addition of ra­
diolabeled proline to culture medium, low molecular weight 
hydroxyproline was found within 8 minutes in the cells but not 
in the culture medium. Since collagen synthesis, processing, 
and secretion requires about :30 minutes, the early presence of 
hydroxyproline in low molecular weight form dearly indicated 
collagen degradation prior to secretion. 
In addition, these workers performed several important con­
trol experiments. The possibility that the low molecular weight 
hydroxyproline containing species represented partially com­
pleted collagen chains which had undergone hydroxylation 
while still bound to the ribosome was exluded by two experi­
ments: (1) The majority of hydroxyproline was found to be in 
a relatively homogeneous population of very small fragments 
(partially completed nascent chains would likely be present as 
a range of variably sized fragments); and (2) timed experiments 
showed that the small hydroxyproline containing species were 
not converted to complete collagen chains. The possibility that 
phagocytosis of extracellular collagen contributed to the for­
mation of low molecular weight hydroxyproline was excluded 
by studies demonstrating that exogenous collagen added to 
cultures could be recovered intact. The possibility that some 
unusual metabolic pathway might be producing labeled hy­
droxyproline de novo was excluded since the amount of degra­
dation observed in these studies (10-:30%) was about the same 
whether hydroxyproline or hydroxylysine was utilized as a 
marker. Lastly, extracellular degradation was demonstrated to 
be minimal since (1) the test cells produced no active collagen­
ase, (2) the addition of extracellular protease inhibitors had no 
effect on the collagen degradation observed, and (:3) exogenous 
collagen added to these cultures was recovered intact. 
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Taken together, these observations indicated that a portion 
of collagen molecules are degraded rapidly after synthesis and 
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excluded the possibility that the low molecular weight hydrox­
yproline represents the degradation of secreted collagen either 
extracellularly or following phagocytosis. 
Widespread Nature of Intracellular Degradation: in vitro 
Studies 
The rapid degradation of newly synthesized collagen has 
been demonstrated in a number of in vitro studies (Table) . 
Although the early studies which demonstrated the rapid deg­
radation of newly synthesized collagen and the rapid formation 
of hydroxyproline following the addition of radioactive proline 
to various experimental systems were not specifically designed 
to demonstrate the intracellular degradation of newly synthe­
sized collagen , they do present evidence which supports the 
concept that rapid, likely intracellular, degradation of collagen 
occurs in many tissues. For example, Daughaday and Mariz 
reported the presence of low molecular weight hydroxyproline 
within 2 hr after the addition of labeled proline to rat cartilage 
in culture [6]. They showed that this material accumulated at 
a linear rate for the duration of the labeling period, and, in 
addition, demonstrated that an extracellular pool of collagen 
could not be the source of the low molecular weight hydroxy­
proline. Taken together, these data are similar to that of Bien­
kowski, Baum, and Crystal for lung fibroblast cultures [13] and 
suggest that in rat cartilage there is also rapid intracellular 
degradation of a portion of newly synthesized collagen. 
Similar evidence in support of the intracellular degradation 
of newly synthesized collagen also exists for other tissues and 
cells (Table). Low molecular weight hydroxyproline has been 
observed within 15 min following the addition of labeled proline 
to cultures of fetal chick skin [9] and to intact chick embryos 
[15]. Furthermore, low molecular weight hydroxyproline accu­
lumates at a constant rate in cultures of fetal chick skin [9] , 
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fetal mouse calvaria [7], and guinea pig granulomata [16]. The 
rapid formation of low molecular weight hydroxyproline has 
also been demonstrated in cells derived from tendon (Berg RA, 
personal communication), lens [8], gingiva [17], liver [18], and 
skin [9,17,19,20], as well as from lung [13]. 
The Widespread Nature of Intracellular Degradation: in 
vivo Studies 
A variety of in vivo studies also offer evidence in support of 
the widespread nature of intracellular degradation of newly 
synthesized collagen (Table). The experimental design of most 
of these studies involves the injection of radiolabeled proline 
into live animals and evaluating the specific activity and the 
time course of hydroxyproline excreted in the urine. These 
kinetic studies suggest that significant amounts of urinary hy­
droxyproline originate from a pool of collagen with a half life of 
no more than several hours in man [21] or in rat [10]. In 
addition, labeled hydroxyproline is detectable in the urine soon 
after the labeled proline is administered in monkey [22] and 
guinea pig [to], in agreement with the concept that a pool of 
rapidly degraded collagen exists in vivo. Moreover, the specific 
activity of the excreted hydroxyproline in these studies is very 
high suggesting that little degradation of mature, unlabeled 
collagen is taking place and that this rapid degradation is 
selective for newly synthesized collagen chains. 
Further in vivo evidence in support of intracellular degrada­
tion in specific tissues has been presented by Schneir and 
colleagues who have detected low molecular weight hydroxy­
proline in skin, aorta, and intestine after the injection of labeled 
proline into rats [23,24]. Two lines of evidence strongly suggest 
that his in vivo collagen degradation was due to an intracellular 
process. First, the high specific activity of the low molecular 
TABLE 1. Rapid degradation of newly synthesized collagen 
Experi- Percentage of newly synthe-mental De- Tissue Species sized collagen Reference sign degraded 
In vitro Skin (em- Chick 16 
bryo) 
Calvaria Rat 25-30 4,47 
(embryo) Mouse 20-30 7 
Mandible Chick 40 46 
Cartilage Rat 15-25 6 
Lens Chick 26 8 
Granuloma Guinea pig 16 
Lung Human Rabbit 20-40 14 
Hamster 6-24 51 
Embryo Chick 10 15 
(whole) 
Cells 
In vitro Fibroblast Mouse 30-32 17,48 
skin Human 30 9, 19 
Calf 30 20 
Tendon Chick 17,53 
Lens Chick 34 8 
Lung Human 10,30 13, 35,39 
Gingiva Mouse 30 17 
3T6 Mouse 20,60 38 
37 55 
45 37 
Hepatocyte Rat 90 18 
In vivo Whole ani- Rat 10,11,56 
mal Guinea pig 57 
Monkey 22 
Man 58,21 
Skin Rat 8h 23, 24 
Guinea pig 10h 25 
Intestine Rat 9h 2:3 
Aorta Rat 23 
" Rapid degradation detected but quantitative data not available. 
h Values probably represent an underestimate; see text for discussion. 
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weight hydroxyproline peptides indicated a maximal amount of 
degradation soon after synthesis. Second, although an increase 
in the percentage of rapid degradation was present in skin of 
diabetic rats, in mixing experiments in vitro, diabetic skin did 
not cause the degradation of newly synthesized collagen pro­
duced by normal skin, thus excluding an extracellular mecha­
nism for collagen degradation. 
Quantitive Studies of Intracellular Degradation 
In general, all quantitative studies of intracellular degrada­
tion in normal cells for which data are available are quite 
similar, demonstrating 10-40% of newly synthesized collagen 
being degraded (Table). The hepatocyte appears to be an 
exception to this rule; hepatocyes in culture degrade 90% of 
newly synthesized collagen [18]. It is not known whether this 
high level of intracellular degradation found in hepatocyte 
cultures reflects a special property of these cells, a general 
property of epithelial cells, or if this result depends on the 
specific conditions utilized in this study. 
Interestingly, in spite of technical limitations of making such 
measurements in vivo, the available quantitative data for in 
vivo estimates of intracellular collagen degradation agree well 
with the in vitro estimates. For example, Schneir et al [23,24] 
have estimated intracellular degradation to be 8% in skin and 
9% in intestine based on a 4 hr labeling period, in good agree­
ment with Barnes et al [25] who observed 9% of hydroxyproline 
to be present in low molecular weight form in guinea pig skin 
in vivo. While these values are somewhat lower than those 
obtained by in vitro methods, both of these investigators pres­
ent evidence that the low molecular weight species are cleared 
rapidly from tissues. This is consistent with the urinary excre­
tion data and suggests that the estimates of 8-9% represent a 
lower limit for the rapid degradation of newly synthesized 
collagen. 
Intracellular Degradation Compared to Extracellular 
Degradation 
It is quite clear that the intracellular degradation of newly 
synthesized collagen and the extracellular degradation of col­
lagen by specific neutral proteases are distinct processes. How­
ever, in some tissues, intracellular and extracellular degradation 
of collagen appear to take place simultaneously. For example, 
in gingival fibroblasts [17], in intact chick lens [8], and in 
cultured lens cells [8], labeled proline is rapidly converted to 
low molecular weight hydroxyproline suggesting collagen deg­
radation. However, the addition of extracellular protease inhib­
itors results in a decrease in the amount degraded, indicating 
extracellular collagen degradation. Importantly, however, some 
collagen degradation occurs even in the presence of these extra­
cellular protease inhibitors. Thus, although Grant, Kefalides, 
and Prockop found that the addition of serum completely 
blocked the degradation of labeled extracellular collagen added 
to cultured lens cells, the degradation of newly synthesized 
collagen still constituted greater than 20% of collagen synthesis, 
and therefore must represent an intracellular process [8]. Sim­
ilarly, Roszkowski and Sauk observed that extracellular pro­
tease inhibitors could block much, but not all, of the degrada­
tion of newly synthesized collagen in gingival cell cultures 
[17]. Studies of the specific activity of the hydroxyproline found 
in low molecular weight fragments under these conditions in­
dicated that the most recently synthesized collagen was being 
degraded while older, extracellular collagen, if degraded at all, 
was degraded at a much lower rate. Thus, extracellular protease 
inhibitors could decrease extracellular collagen degradation 
while the simultaneous intracellular degradation of newly syn­
thesized collagen was unaffected. 
That many cell types can produce proteases capable of de­
grading collagen is well known [26], and that some extracellular 
degradation of collagen might occur in some systems in which 
intracellular degradation is simultaneously occurring is not 
suprising. However, the available evidence indicates that the 
intracellular degradation of collagen is a widespread process 
which can occur simultaneously with extracellular collagen 
degradation. It is likely that these 2 pathways for the destruc­
tion of collagen molecules play very different roles in the 
metabolism of collagen. 
Intracellular Degradation of Secreted Proteins Other Than 
Collagen 
Recent studies indicate that collagen is not the only secreted 
protein subject to intracellular degradation. Insulin [27,28], 
parathyroid hormone [29-31], and prolactin [32] all appear to 
be subject to intracellular degradation within the cell prior to 
secretion. Interestingly, in the case of these hormones, the 
degradation appears to be selective for recently synthesized 
molecules that are resident within an intracellular storage pool 
and appears to regulate the amount available for secretion in 
response to a variety of physiologic stimuli. 
ROLE OF INTRACELLULAR DEGRADATION OF 
NEWLY SYNTHESIZED COLLAGEN IN THE 
CELLULAR CONTROL OF COLLAGEN PRODUCTION 
Current concepts suggest that the intracellular degradation 
of newly synthesized collagen serves two distinct roles in mod­
ulating collagen production. First, intracellular collagen degra­
dation provides a mechanism for the destruction of defective 
molecules before their secretion, thus preventing the incorpo­
ration of defective molecules into the extracellular matrix. 
Second, intracellular degradation provides one means to regu­
late the amount of collagen and the relative amounts of collagen 
types produced by cells in response to certain extracellular 
mediators. 
Degradation of Defective Molecules 
The formation of the triple helical structure of the collagen 
molecule requires severe constraints on the amino acid com­
position of the component polypeptide chains [1,33]. Since 
collagen is a large molecule with nearly 1,000 amino acid 
residues per chain, even a very small percentage of errors would 
result in the production of significant amounts of abnormal 
molecules. For example, every third amino acid must be a 
glycine to allow the chains to properly fold into a triple helix 
[1,33]; substitution of a glycine residue with another amino acid 
results in a molecule that can not assume a normal conforma­
tion. In addition, the hydroxyprolyl residues in the collagen 
chain are also required for a stable triple helical structure 
[1,33]. Thus, it is possible that intracellular degradation of 
newly synthesized collagen could function as a cellular "quality 
control" mechanism to rapidly destroy any abnormal molecules 
that might be synthesized. 
Support for the hypothesis that intracellular degradation 
selectively disposes of abnormal collagen comes from 3 lines of 
evidence. 
First, incubation of cell" with the analogues of proline such 
as cis-hydroxyproline or azetidine result in the incorporation of 
these analogues into collagen molecules that can not assume a 
stable triple helix [34]. In both situations, there is an increase 
in the amount of collagen degraded within the cell [13,35]. 
Second, when hydroxylation of proline is blocked, cells pro­
duce abnormal, underhydroxylated collagen; these circum­
stances are associated with an increase in the proportion of 
newly synthesized collagen which is rapidly degraded [36-38]. 
For example, in the absence of ascorbate, lung fibroblasts 
degrade up to 60% of newly synthesized collagen [36], a 4- to 6-
fold increase in baseline intracellular collagen degradation. In­
terestingly, some of the abnormal collagen chains produced by 
these cells are still secreted, suggesting that the mechanism of 
intracellular degradation may have a limited capacity, i.e., in 
the absence of ascorbate, abnormal molecules can still 
"overflow" into the extracellular space. If such "overflow" oc-
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curs in cell types which also secrete proteases capable of extra­
cellular collagen degradation, this may account for the increase 
in extracellular degradation of collagen sometimes observed 
when cells produce abnormal collagen. 
Third, lung fibroblasts underhydroxylate collagen during the 
log phase of growth; this condition is associated with a nearly 
3-fold increase in the proportion of newly synthesized collagen 
degraded intracellularly over that observed when cells achieve 
confluency [39]. 
Taken together, these experiments clearly support the con­
cept that abnormal collagen molecules can be detected within 
the cell and shunted into a degradative pathway. 
Intracellular Site of Degradation of Defective Collagen 
Molecules 
Studies with lung fibroblasts have demonstrated that the 
increase in intracellular degradation that occurs in association 
with the formation of abnormal collagen chains is due to a 
lysosomal process [35,40]. For example, inhibitors of lysosomal 
proteolytic activity block the increased intracellular degrada­
tion that occurs when cells make defective collagen. Moreover, 
the decrease in production of low molecular weight hydroxy­
proline containing fragments in the presence of inhibitors of 
lysosomal function is accompanied by an accumulation of hy­
droxyproline containing material within lysosomes [35]. Al­
though one study of ascorbate deficient rat skin fibroblasts 
showed no decrease in the percentage of intracellular degrada­
tion with lysosomal inhibitors [17], in this case, only the me­
dium and an acetic acid extract of the cell layers was analyzed, 
and therefore, intralysosomal material was not fully accounted 
for, i.e., the effect of lysosomal inhibitors may have been un­
derestimated. 
Further support of the localization of intracellular degrada­
tion to a lysosomal site derives from studies of Karim, Cournil, 
and Leblond [41] which demonstrate material within lysosom9s 
that was antigenic ally cross reactive with procollagen. This 
material appears to reach lysosomes by way of the endoplasmic 
reticulum and the Goigi apparatus where collagen containing 
microvesicular bodies are formed. Interestingly, such microves­
icular bodies have also been implicated in mediating the lyso­
somal destruction of other intracellular components [42]. 
Although the available evidence supports the concept that a 
lysosomal process is involved in the increased intracellular 
degradation of newly synthesized collagen that occurs with the 
production of defective molecules, lysosomal inhibitors do not 
inhibit all intracellular degradation [17,35,40]. In the )Jresence 
of these agents approximately 10% of newly synthesized colla­
gen molecules are still degraded. Thus, in some circumstances, 
intracellular extralysosomal processes may be important for the 
intracellular degradation of collagen. 
Intracellular Degradation of Newly Synthesized Collagen as 
a Mechanism for Control of Collagen Production 
Intracellular degradation of newly synthesized collagen is one 
means by which cells regulate collagen production in response 
to exogenous mediators. For example, intracellular degradation 
is important in the response of lung and skin fibroblasts to 
stimuli which affect the cAMP system [43]. Agents which 
elevate cAMP in these cells also cause an increase in the 
intracellular degradation of newly synthesized collagen with a 
corresponding decrease in the amount of collagen :-;ecreted. 
Moreover, the effect of elevated levels of cAMP appears to be 
selective in increasing the degradation of type I collagen, i.e., 
the production of type III collagen by these cells appears to be 
unaffected by cAMP levels [44]. In this context, since certain 
properties of the extracellular matrix may critically depend on 
the ratio of collagen types present, intracellular degradation 
may play an important role in regulating matrix composition 
[ 45]. 
Although intracellular degradation of collagen has been noted 
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in bone [7,46] (Kream BE and Raisz LG, personal communi­
cation) and cartilage [6], tissues where collagen production is 
sensitive to hormonal control, the relative role of intracellular 
degradation in the control of collagen production in these sites 
is just beginning to be understood. In cultured bone, for exam­
ple, intracellular degradation appears to be less important than 
other mechanisms for the control of collagen production [47]. 
Thus, the quantitative importance of intracellular degradation 
in the control of collagen synthesis is likely to be different in 
various tissues. 
Control of Intracellular Degradation 
Several lines of evidence suggest that widely differing cellular 
events can lead to the intracellular degradation of newly syn­
thesized collagen. First, agents which increase cAMP within 
cells do not affect the degree of prolyl hydroxylation [43]; i.e., 
the effects of cAMP on collagen degradation are not mediated 
through changes in the conformation of the collagen molecule. 
Second, under circumstances where collagen is underhydroxy­
lated, production of both types I and III collagen is reduced 
[36] (Rennard SI, Berg RA, and Crystal RG, unpublished 
observations); in contrast, the cAMP mediated effect is specific 
in decreasing the amount of type I [44]. Thus the cell can 
increase intracellular degradation of newly synthesized collagen 
in a different fashion in response to different stimuli. Third, 
intracellular degradation has also been observed to be increased 
in skin fibroblasts following a phagocytic stimulus [48] although 
it is unknown whether this event affects either intracellular 
cAMP or the degree of hydroxylation of collagen. Together, 
these results strongly suggest that more than one cellular 
pathway leads to the intracellular degradation of newly synthe­
sized collagen. 
INTRACELLULAR DEGRADATION OF NEWLY 
SYNTHESIZED COLLAGEN AND DISEASE STATES 
Very few disease states have been studied with regard to a 
pathogenic role for intracellular degradation of newly synthe­
sized collagen. Although it is possible that abnormal intracel­
lular degradation of collagen on a congenital basis may contrib­
ute to one of the primary heritable collagen disorders, this 
phenomenon has only been studied in skin fibroblasts from 
patients with osteogenesis imperfecta, a group of inherited 
disorders characterized by the underproduction of type I col­
lagen. In these cells, intracellular degradation of collagen is 
normal and does not appear to contribute to the disease process 
[19]. In acquired diseases, however, current evidence suggests 
a role for intracellular degradation in 3 distinct disease states: 
fibrosis, diabetes mellitus, and scurvy. 
Fibrosis is a state characterized by an abnormal accumulation 
of connective tissue and can result from a wide variety of causes. 
Several separate lines of evidence suggest a role for intracellular 
degradation in certain types of fibrosis. 
1. Fibrosis has been associated with ,B-blocking drugs such 
as propanolol or practolol, and may be due to a pharmacologic 
interruption in the control of intracellular degradation of col­
lagen [49]. As detailed above, ,B-agonists, by increasing intra­
cellular cAMP levels, induce an increase in the intracellular 
degradation of collagen and reduce collagen production by 
certain fibroblasts [43,44]. ,B-blocking drugs, by interfering with 
this mechanism [49], could prevent ,B-agonist mediated sup­
pression of collagen production and thus contribute to an ov­
erproduction of collagen which could result in fibrosis. 
2. Certain inflammatory states, characterized by the devel­
opment of fibrosis, may also result from interference with the 
normal ,B-agonist mediated mechanisms that suppress collagen 
production by increasing intracellular degradation. In these 
conditions, however, the interference in the regulation of col­
lagen production is likely mediated by the proteolytic enzymes 
released by inflammatory cells resulting in proteolytic attack of 
fibroblast cell surface ,B-agonist receptors. As a result, in the 
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presence of inflammation, some cells may overproduce type I 
collagen since these cells could not respond to suppressive /3-
agonist regulation of collagen production. In support of this 
hypothesis, the in vitro treatment of lung fibroblasts with either 
trypsin or leukocyte elastase results in the loss of isoproterenol 
mediated suppression of type I collagen [50]. 
3. Bleomycin, a chemotherapeutic drug used in the treat­
ment of certain cancers, can cause pulmonary fibrosis. Experi­
mental studies with this drug have demonstrated that many 
changes are induced in affected lung tissue, including inflam­
mation, increased collagen synthesis, and a 3-fold increase in 
intracellular degradation of newly synthesized collagen [51]. 
Although it is currently unknown which effects are primary and 
which are secondary, (or even which cell types are being af­
fected in this disease process), it is likely that the changes in 
intracellular degradation of newly synthesized collagen contrib­
ute to the altered connective tissue formation caused by bleo­
mycin exposure. 
Diabetes mellitus is associated with a variety of abnormalities 
of connective tissue including the atrophy of skin. Schneir et al, 
have demonstrated, in vivo, that the skin of diabetic rats 
degrades a much larger portion of newly synthesized collagen 
than does normal skin, and that this increase in degradation 
can account for much of the atrophy seen in the skins of these 
animals [23,24]. Although the mechanism which leads to the 
increased degradation of newly synthesized collagen in the 
diabetic skin and the relationship of this process to other 
atrophic conditions are unknown, it is possible that such pro­
cesses could be important in the pathogenesis of these clinically 
significant conditions. 
Scurvy is the clinical syndrome which follows the prolonged 
deficiency of ascorbic acid. Without this vitamin, collagen can 
not be adequately hydroxylated and, as a result, abnormal, 
nonhelical collagen chains are formed [52]. Since a large portion 
of these molecules are degraded within the cell, collagen pro­
duction is dramatically reduced in scurvy [36]. Moreover, as 
noted above, the pathway of intracellular degradation can be 
overwhelmed, resulting in the secretion of some abnormal 
chains which, conceivably, could be incorporated into extracel­
lular matrix and result in abnormal connective tissue. It is 
therefore likely that in scurvy the decreased production of 
normal molecules and the secretion of abnormal molecules both 
contribute to the connective tissue abnormalities present. 
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